BLA 761428 · Novo Nordisk INC
Alhemo
Concizumab · Injection
OrphanLast checked: Nov 20, 2026Latest source record: Jul 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 31, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
3 Phase 3, 0 recruiting
FAERS reports
45
36 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 31, 2025 Original approval · Type 9 - New indication submitted as distinct BLA, consolidated OrphanLetterLabelMedication Guide
3 products under this application
- ALHEMO · CONCIZUMAB 300MG/3ML (100MG/ML) · SOLUTION, INJECTION · Prescription
- ALHEMO · CONCIZUMAB 60MG/1.5ML (40MG/ML) · SOLUTION, INJECTION · Prescription
- ALHEMO · CONCIZUMAB 150MG/1.5ML (100MG/ML) · SOLUTION, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Concizumab" as an intervention, any sponsor and status, largest first.
- Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without InhibitorsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04082429 · 156 participants · Start Nov 13, 2019 · Primary completion Jul 12, 2022
Drug: Concizumab · For: Haemophilia A Without Inhibitors; Haemophilia B Without Inhibitors
Sites: Los Angeles, California; Orange, California; Augusta, Georgia · 113 sites in all
- A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without InhibitorsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05135559 · 153 participants (planned) · Start Mar 24, 2022 · Primary completion Apr 21, 2026
Drug: Concizumab · For: Haemophilia A and B With and Without Inhibitors
Sites: San Diego, California; Aurora, Colorado; Orlando, Florida · 91 sites in all
- Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With InhibitorsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04083781 · 134 participants · Start Oct 21, 2019 · Primary completion Dec 27, 2021
Drug: Concizumab · For: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Sites: Orange, California; Atlanta, Georgia; Indianapolis, Indiana · 99 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03196297 · 36 participants · Start Aug 16, 2017 · Primary completion Jun 22, 2018
Drug: Concizumab; Turoctocog alfa · For: Haemostasis; Haemophilia A
Sites: Los Angeles, California; Indianapolis, Indiana; Oklahoma City, Oklahoma · 31 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT03196284 · 26 participants · Start Aug 10, 2017 · Primary completion Sep 19, 2018
Drug: Concizumab; Eptacog alfa · For: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Sites: Los Angeles, California; Indianapolis, Indiana; Iowa City, Iowa · 22 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02490787 · 24 participants · Start Sep 10, 2015 · Primary completion Oct 14, 2016
Drug: Concizumab; placebo · For: Congenital Bleeding Disorder; Haemophilia A
Sites: Torrance, California; Indianapolis, Indiana; Iowa City, Iowa · 34 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- haemarthrosis11
- fall4
- condition aggravated3
- haematoma muscle3
- injection site pain3
- muscle haemorrhage3
- anti factor ix antibody increased2
- contusion2
- death2
- haematoma2
- haematuria2
- haemorrhage2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 27 |
| 2026 | 17 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
Matsushita T, Shapiro A, Abraham A, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.
Mahlangu J, Boban A, Bruzelius M, et al. · Blood Adv 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
Chowdary P, Angchaisuksiri P, Apte S, et al. · Lancet Haematol 2024 · Multicenter Study, Randomized Controlled Trial
- A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Eichler H, Angchaisuksiri P, Kavakli K, et al. · J Thromb Haemost 2018 · Clinical Trial, Phase I, Multicenter Study
- Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.
Young G, Angchaisuksiri P, Apte S, et al. · Blood Adv 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review.
Siddiqui E, Khalid M, Khan MS, et al. · Clin Appl Thromb Hemost 2025 · Systematic Review
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.